Skip to main content
          Skip to FDA Search
          Skip to in this section menu
          Skip to footer links


U.S. flagAn official website of the United States government

					Here’s how you know
          			Dot gov**The .gov means it’s official.**Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
							      SSL**The site is secure.** The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. 
			U.S. Food and Drug Administration
				
        Search
            Menu
							
						Search FDA
									
									Submit search 
		Featured
							Contact FDA
	                FDA Guidance Documents
	                Recalls, Market Withdrawals and Safety Alerts
	                Press Announcements
	                Warning Letters
	                Advisory Committees
	                En Español

					Products
            Food
							Drugs
							Medical Devices
							Radiation-Emitting Products
							Vaccines, Blood, and Biologics
							Animal and Veterinary
							Cosmetics
							Tobacco ProductsTopics
            About FDA
							Combination Products
							Regulatory Information
							Safety
							Emergency Preparedness
							International Programs
							News and Events
							Training and Continuing Education
							Inspections and Compliance
							Science and ResearchInformation For
            Consumers
	            Patients
	            Industry
	            Health Professionals
	            Federal, State and Local Officials 
 In this section:

                Oncology Center of Excellence

Oncology Center of Excellence

                        Who We Are - Oncology Center of Excellence
          Project Patient Voice


                        OCE Annual Reports
          Project Community Home
          About FDA
          FDA Organization
          Oncology Center of Excellence
          Project Renewal FAQOncology Center of Excellence Project Renewal FAQ
  
  	
    Share
    Post
    Linkedin

    Email
    PrintWhat does Project Renewal aim to do?
	The FDA-approved prescribing information serves as the primary source of information for the safe and effective use of drugs. Project Renewal is a collaborative program that leverages external oncology experts to review publicly available data in the literature to update certain older oncology drug prescribing information to ensure this information is clinically meaningful and scientifically up to date.


Who does this aim to help?
	Project Renewal is intended to help inform the provider community responsible for caring for cancer patients. This includes oncologists, advanced practice providers, registered nurses, and pharmacists at community and specialty pharmacies who use FDA prescribing information to inform clinical decisions and patient care. When applicable, revisions made to the prescribing information are also included in Patient Information, using nontechnical language to ensure safe and effective use.


Does this initiative seek to update the layout of the prescribing information as well?
	Some older cancer drugs have prescribing information inconsistent with current regulations and guidance intended to make labeling more informative and easier to navigate. In addition to updating content with current scientific evidence, Project Renewal will ensure the prescribing information is in Physician Labeling Rule (PLR) and Pregnancy and Lactation Labeling Rule (PLLR) format. The PLR offers a consistent format for information that healthcare providers access, including dosage and administration, adverse reactions, drug interactions, and use in specific populations. The PLLR format includes information on the drug’s use during pregnancy and lactation, and in patients with reproductive potential.


Who is involved in the Project Renewal Process?
	Scientific Expert Teams: Research teams are made up of external scientific experts who review the Project Renewal product's prescribing information and evaluate the publicly available evidence to determine what should be updated in the prescribing information.
	Fellows: Hematology and oncology fellows from academic training programs evaluate published literature and contribute to recommended updates to the prescribing information, while learning about FDA requirements for drug approval. This provides a unique "hands on" educational experience within the Project Renewal initiative.
	FDA: FDA staff participate in discussions with external oncologists to discuss the publicly available data for each drug and provide education on regulatory requirements for updating the prescribing information. Upon completion of evidence evaluation, the FDA team will conduct a full independent review of the proposed update recommendations and provide the final proposed prescribing information changes to the reference listed drug (RLD) holder.
	RLD Holders: Upon review of the FDA's proposed chances to the prescribing information, RLD holders will submit a supplemental application to their New Drug Application (NDA). RLD holders will be able to negotiate the final prescribing information during the supplemental application review period.


What kind of products will go through this process?
	Project Renewal is focused on the evaluation of long-standing drugs with decades of clinical experience and use. Drugs on the market for over 20 years may not be in PLR/PLLR format, may have standard of care uses that are not included in the labeling or have outdated information. Many of these older drugs are important components of standard multi-agent chemotherapy regimens, some of which have curative potential. Project Renewal incorporates a standardized process of evaluating publicly available scientific information to support updates to the prescribing information, including potential new indications and dosage regimens. Several factors increase the acceptability of relying on published reports to support approval of a new use, including having multiple studies conducted by different investigators with consistent findings across studies, a high level of detail in the published reports (including statistical methods and analysis plans), appropriate endpoints that can be objectively assessed, robust results achieved by protocol-specified analyses, and studies conducted by research groups with a history of implementing high quality studies. Drugs selected for Project Renewal have decades of safety and other clinical data. Project Renewal is not intended for drugs approved in more recent years with more contemporary and relatively current prescribing information.

Are there other goals of Project Renewal outside of labeling updates themselves?
	Yes! Project Renewal has engagement and educational value. In collaborating with the Oncology community, the program has led to interaction with scores of academic oncologists and multidisciplinary scientists and trainees across the country. This serves as a platform for FDA Oncology to increase awareness of FDA product labeling as well as educate the oncology community on FDA’s regulatory and evidentiary framework.

What products have been updated under Project Renewal?
	Multiple oncology drugs have been evaluated through Project Renewal and are in the various stages of independent FDA review and final supplement request preparation. The RLD holders will receive an official Prior Approval Supplement (PAS) request with the necessary information for their labeling updates.

**Project Renewal Approvals**

**Drug Name**
			**Approval Date**
			**Additional Resources**Temodar (temozolomide)
			September 14, 2023
			Approval Announcement

			Prescribing Information

			FDA ReviewXeloda (capecitabine)
			December 14, 2022
			Approval Announcement

			Prescribing Information

			FDA Review

For Additional Information

About Oncology Prescription Drug Labeling
	How Do I Use Prescription Drug Labeling

                                                                                  Content current as of:
      10/05/2023Oncology Center of Excellence

          
                        Who We Are - Oncology Center of Excellence
          Project Patient Voice


                        OCE Annual Reports
          Project Community
 
 Footer Links
    FDA Archive
          About FDA
          Accessibility
      Visitor Information
          Website Policies / Privacy
          No FEAR Act
          Vulnerability Disclosure Policy
      FOIA
          HHS.gov
          USA.gov
    Contact FDA
      Follow FDA on Facebook
      Follow FDA on X
      Follow FDA on Instagram
      Follow FDA on LinkedIn
      View FDA videos on YouTube
      Subscribe to FDA RSS feeds
    FDA Homepage
    Contact Number
      1-888-INFO-FDA (1-888-463-6332) Back toTop